Provided by Tiger Trade Technology Pte. Ltd.

Eledon Pharmaceuticals, Inc.

2.83
-0.1300-4.39%
Post-market: 2.80-0.0300-1.06%18:01 EDT
Volume:864.50K
Turnover:2.44M
Market Cap:214.66M
PE:-5.08
High:3.03
Open:2.96
Low:2.75
Close:2.96
52wk High:4.60
52wk Low:1.35
Shares:75.85M
Float Shares:68.58M
Volume Ratio:0.46
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5566
EPS(LYR):-0.5566
ROE:-35.79%
ROA:-30.04%
PB:1.57
PE(LYR):-5.08

Loading ...

Nov 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 13, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 13, 2024

Major Issues Report

Form 8-K - Current report
Nov 05, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 05, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Oct 31, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Oct 31, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Oct 30, 2024

Major Issues Report

Form 8-K - Current report
Oct 29, 2024

Major Issues Report

Form 8-K - Current report
Oct 02, 2024

Major Issues Report

Form 8-K - Current report
Sep 30, 2024

Correspondence

Form CORRESP - Correspondence
Sep 20, 2024

Major Issues Report

Form 8-K - Current report
Aug 19, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 19, 2024

[Rev.]Quaterly Report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
Aug 19, 2024

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Aug 14, 2024

Major Issues Report

Form 8-K - Current report
Jul 12, 2024

Major Issues Report

Form 8-K - Current report
Jul 10, 2024

Major Issues Report

Form 8-K - Current report
Jul 10, 2024

Major Issues Report

Form 8-K - Current report
Jun 03, 2024

Correspondence

Form CORRESP - Correspondence